Pathstone Holdings’s Blueprint Medicines BPMC Stock Holding History

Pathstone Holdings’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-27,464	Closed	-$3.52M	–	2339
2025 Q2	$3.52M	Buy	27,464 +1,019	+4%	+$106K	0.01%	691
2025 Q1	$2.34M	Buy	26,445 +4,545	+21%	+$443K	0.01%	896
2024 Q4	$1.91M	Buy	21,900 +1,769	+9%	+$162K	0.01%	996
2024 Q3	$1.86M	Sell	20,131 -2,085	-9%	-$207K	0.01%	1014
2024 Q2	$2.39M	Buy	22,216 +5,678	+34%	+$568K	0.01%	838
2024 Q1	$1.57M	Buy	16,538 +13,119	+384%	+$1.13M	0.01%	1032
2023 Q4	$315K	Buy	+3,419	New	+$222K	﹤0.01%	1788

Other funds holding BPMC

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Pathstone Holdings's BPMC Position: Q3 2025 in Review

Pathstone Holdings sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 27,464 shares — an estimated $3.52M sold.

Pathstone Holdings first reported a position in BPMC in Q4 2023 and held it in 7 quarters. The position peaked at $3.52M in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

Pathstone Holdings reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
Pathstone Holdings sold 27,464 Blueprint Medicines shares in Q3 2025, an estimated $3.52M.
Pathstone Holdings first reported a position in Blueprint Medicines in Q4 2023 and held it in 7 quarters.
Pathstone Holdings's Blueprint Medicines position peaked at $3.52M in Q2 2025.
5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Pathstone Holdings's 13F filing for Q3 2025, filed 13 Nov 2025.